A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel
- First Posted Date
- 2013-02-21
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 47
- Registration Number
- NCT01795703
A Study to Assess Learning Performance in Patients With Schizophrenia and Young and Elderly Healthy Volunteers
Early Phase 1
Completed
- Conditions
- Schizophrenia
- Interventions
- Behavioral: Cognitive Test Battery 1Behavioral: Cognitive Test Battery 2
- First Posted Date
- 2013-02-11
- Last Posted Date
- 2014-06-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 51
- Registration Number
- NCT01788436
A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants
- First Posted Date
- 2013-01-31
- Last Posted Date
- 2013-08-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 58
- Registration Number
- NCT01780259
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
Phase 2
Completed
- Conditions
- Lymphoma
- Interventions
- Drug: PCI-32765 (Ibrutinib)
- First Posted Date
- 2013-01-30
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 110
- Registration Number
- NCT01779791
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
Phase 3
Completed
- Conditions
- Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2013-01-28
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 523
- Registration Number
- NCT01776840
A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment
- First Posted Date
- 2013-01-15
- Last Posted Date
- 2014-10-07
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT01767948
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 643
- Registration Number
- NCT01767857
- Locations
- 🇺🇸
The Center for Cancer and Blood Disorders, a Division of Regional Cancer Care Associates LLC., Bethesda, Maryland, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Good Samaritan Hospital Corvallis - SHOC, Corvallis, Oregon, United States
A Study to Assess the Effect of Rifampin on the Pharmacokinetics of PCI-32765 in Healthy Participants
- First Posted Date
- 2013-01-08
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 18
- Registration Number
- NCT01763021
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
- First Posted Date
- 2012-12-27
- Last Posted Date
- 2017-10-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT01756638
A Study to Assess the Relative Bioavailability of 4 Formulations of Fentanyl Transdermal System Compared Against DUROGESIC Fentanyl Transdermal Patch After Single Application in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2014-03-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT01717157
© Copyright 2025. All Rights Reserved by MedPath